Aprea Therapeutics, Inc.
APRE Healthcare Biotechnology
Aprea Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $285,800.00, down 81.0% from fiscal 2024. In the quarter to June 2026, revenue fell 98.4%, EPS grew 86.8% and free cash flow fell 5.22%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow APRE
Aprea Therapeutics, Inc. (APRE) EV/Sales
As of 16 October 2026, Aprea Therapeutics, Inc. (APRE) trades at a EV/Sales of −35.7×. Over the past ten years it has ranged from −127× (June 2026) to 39.1× (August 2026); the current reading is higher than 4% of that period. That is below the Biotechnology industry median of 9.2× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | −31.6× | — |
| FY2024 | −3.1× | — |
| FY2023 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Dec 2025 | −31.6× | — |
| Sep 2025 | −8.8× | — |
| Jun 2025 | −7.4× | — |
| Mar 2025 | −5.5× | — |
| 7 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| APRE Aprea Therapeutics, Inc. | −35.7× |
| SNGX Soligenix Inc. compare | −3.7× |
| QNRX Quoin Pharmaceuticals, Ltd. Sponsored ADR compare | n/m |
| CNSP CNS Pharmaceuticals, Inc. compare | n/m |
| MBRX Moleculin Biotech, Inc. compare | n/m |
| CURX Curanex Pharmaceuticals Inc compare | n/m |
| SNTI Senti Biosciences, Inc. compare | 0.3× |
| XTLB XTL Biopharmaceuticals Ltd. compare | 1.3× |
| KPTI Karyopharm Therapeutics Inc. compare | 1.3× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)